Phase II Trial of Mosunetuzumab in Patients With Newly Diagnosed Extranodal Marginal Zone Lymphoma (EMZL) (ML44933)
Latest Information Update: 27 Nov 2024
At a glance
- Drugs Mosunetuzumab (Primary)
- Indications Marginal zone B-cell lymphoma
- Focus Therapeutic Use
- Sponsors Genentech
Most Recent Events
- 25 Nov 2024 Status changed from not yet recruiting to recruiting.
- 29 Aug 2024 New trial record